Regencell Bioscience Holdings Ltd Cash Flow Conversion Efficiency
Regencell Bioscience Holdings Ltd cash flow conversion efficiency. Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has a cash flow conversion efficiency ratio of -2.125x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.59 Million) by net assets ($1.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Regencell Bioscience Holdings Ltd (2003–2025)
Cash flow conversion efficiency of Regencell Bioscience Holdings Ltd from 2003 to 2025. This chart illustrates how Regencell Bioscience Holdings Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Regencell Bioscience Holdings Ltd (RGC) share price today for real-time trading data and today's change.
Regencell Bioscience Holdings Ltd Cash Flow Conversion Ratio Explained
Regencell Bioscience Holdings Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Regencell Bioscience Holdings Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their cash flow conversion efficiency. Also see Regencell Bioscience Holdings Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PUMA SE
XETRA:PUM
|
-0.249x |
|
Pt Pradiksi Gunatama Tbk
JK:PGUN
|
0.059x |
|
Sixt SE
XETRA:SIX2
|
-0.399x |
|
Ningxia Orient Tantalum Industry Co Ltd
SHE:000962
|
-0.065x |
|
Shenzhen SC New Energy Technology Corp Class A
SHE:300724
|
0.003x |
|
Kirloskar Oil Engines Limited
NSE:KIRLOSENG
|
0.097x |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
-0.020x |
|
XTC New Energy Materials Xiamen Co Ltd
SHG:688778
|
0.025x |
Annual Cash Flow Conversion Efficiency for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual cash flow conversion efficiency of Regencell Bioscience Holdings Ltd from 2003 to 2025. Review Regencell Bioscience Holdings Ltd free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $4.86 Million | $-3.11 Million | -0.641x | -31.57% |
| 2024-06-30 | $8.22 Million | $-4.00 Million | -0.487x | -17.62% |
| 2023-06-30 | $11.99 Million | $-4.96 Million | -0.414x | -34.24% |
| 2022-06-30 | $17.08 Million | $-5.27 Million | -0.308x | -260.65% |
| 2021-06-30 | $-4.00 Million | $-767.31K | 0.192x | -29.97% |
| 2020-06-30 | $-2.65 Million | $-726.57K | 0.274x | +28.88% |
| 2019-06-30 | $-1.84 Million | $-390.99K | 0.213x | +144.40% |
| 2018-06-30 | $-855.80 Million | $409.90 Million | -0.479x | +2.12% |
| 2017-06-30 | $-838.90 Million | $410.50 Million | -0.489x | +1.14% |
| 2016-06-30 | $-877.60 Million | $434.40 Million | -0.495x | -26.87% |
| 2015-06-30 | $-894.80 Million | $349.10 Million | -0.390x | +19.77% |
| 2014-06-30 | $-713.40 Million | $346.90 Million | -0.486x | +2.24% |
| 2013-06-30 | $-696.80 Million | $346.60 Million | -0.497x | +19.58% |
| 2012-06-30 | $-570.90 Million | $353.10 Million | -0.618x | -16.90% |
| 2011-06-30 | $-490.30 Million | $259.40 Million | -0.529x | +68.20% |
| 2010-06-30 | $-246.90 Million | $410.80 Million | -1.664x | -49.13% |
| 2009-06-30 | $-242.00 Million | $270.00 Million | -1.116x | +83.40% |
| 2008-06-30 | $-119.00 Million | $800.00 Million | -6.723x | +53.56% |
| 2007-06-30 | $-21.00 Million | $304.00 Million | -14.476x | -216.26% |
| 2006-06-30 | $31.00 Million | $386.00 Million | 12.452x | +128.44% |
| 2005-06-30 | $71.00 Million | $387.00 Million | 5.451x | +813.79% |
| 2004-06-30 | $798.00 Million | $476.00 Million | 0.596x | +103.73% |
| 2003-06-30 | $1.27 Billion | $373.00 Million | 0.293x | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more